(Q39374283)

English

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

based on heuristic

inferred from title

Attila A Seyhan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Usha Varadarajan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sung Choe

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Wei Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Terence E Ryan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

23 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Molecular BioSystems

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1553-1570

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

New approaches to molecular cancer therapeutics

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Antitumor activity of HER-2 inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The consensus coding sequences of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Perspectives: Other ErbB2-Targeted Therapies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Why is cancer drug discovery so difficult?

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Integrated functional, gene expression and genomic analysis for the identification of cancer targets

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

RNAi screening for the discovery of novel modulators of human disease

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A loss-of-function RNA interference screen for molecular targets in cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Dissecting cancer pathways and vulnerabilities with RNAi

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cancer proliferation gene discovery through functional genomics.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Normalization of cDNA microarray data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The genetic landscape of the childhood cancer medulloblastoma

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Bcl-G, a novel pro-apoptotic member of the Bcl-2 family

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

New apoptosis drugs face critical test

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The genomic landscapes of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Mutations in TRIOBP, which encodes a putative cytoskeletal-organizing protein, are associated with nonsyndromic recessive deafness

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Squalene synthase inhibition: a novel target for the management of dyslipidemia

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

FoxP4, a novel forkhead transcription factor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Sodium ion channel mutations in glioblastoma patients correlate with shorter survival

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A pivotal role of cyclic AMP-responsive element binding protein in tumor progression

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Profiling essential genes in human mammary cells by multiplex RNAi screening

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Minimizing the risk of reporting false positives in large-scale RNAi screens

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39374283&oldid=1517028790"